model-informed-drug-development
(2)
Delineate
Delineate is a Cambridge, Massachusetts AI company building agents that accelerate clinical trial design for pharmaceutical and biotech companies. Its custom large language models and computer vision systems extract and structure data from thousands of research papers and patents - including numbers buried inside figures and plots - turning months of manual evidence aggregation into weeks. A Y Combinator Winter 2025 company founded in 2024 by an MIT PhD and an ex-Lockheed Skunkworks AI lead, Delineate works with two top-10 pharmaceutical companies and holds an NIH STTR grant with MIT.
Emily Nieves
Emily Nieves is the co-founder and CEO of Delineate, a Cambridge, Massachusetts startup building AI agents that read the scientific literature the way a pharmacologist does - pulling numbers out of buried plots and patents to speed up drug development. A University of Georgia biological engineer turned MIT PhD researcher, she worked on computational modeling at Pfizer and AstraZeneca before deciding the bottleneck wasn't the models but the months it took to feed them. Delineate, part of Y Combinator's Winter 2025 batch, now works with top-10 pharma companies to turn months of systematic review into weeks.